BR112013014392B1 - Compostos cetolídeos, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos - Google Patents

Compostos cetolídeos, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos Download PDF

Info

Publication number
BR112013014392B1
BR112013014392B1 BR112013014392-4A BR112013014392A BR112013014392B1 BR 112013014392 B1 BR112013014392 B1 BR 112013014392B1 BR 112013014392 A BR112013014392 A BR 112013014392A BR 112013014392 B1 BR112013014392 B1 BR 112013014392B1
Authority
BR
Brazil
Prior art keywords
compound
formula
thiadiazol
pyridin
isoxazol
Prior art date
Application number
BR112013014392-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013014392A2 (pt
Inventor
Bharat Trivedi
Prasad Deshpande
Ravikumar Tadiparthi
Sunil Gupta
Santosh Diwakar
Shivaji Pawar
Vijay Patil
Deepak Dekhane
Mahesh Patel
Satish Bhavsar
Amit MISHRA
Manish Solanki
Mohammad Jafri
Sachin Bhagwat
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Publication of BR112013014392A2 publication Critical patent/BR112013014392A2/pt
Publication of BR112013014392B1 publication Critical patent/BR112013014392B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112013014392-4A 2010-12-09 2011-02-03 Compostos cetolídeos, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos BR112013014392B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3352MU2010 2010-12-09
IN3352/MUM/2010 2010-12-09
PCT/IB2011/050464 WO2012076989A1 (en) 2010-12-09 2011-02-03 Ketolide compounds

Publications (2)

Publication Number Publication Date
BR112013014392A2 BR112013014392A2 (pt) 2016-07-19
BR112013014392B1 true BR112013014392B1 (pt) 2021-09-21

Family

ID=54259620

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013014392-4A BR112013014392B1 (pt) 2010-12-09 2011-02-03 Compostos cetolídeos, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos

Country Status (18)

Country Link
US (2) US9175031B2 (enExample)
EP (2) EP2673285B1 (enExample)
JP (2) JP5851516B2 (enExample)
KR (1) KR101657751B1 (enExample)
CN (2) CN103384676B (enExample)
AU (1) AU2011340204B2 (enExample)
BR (1) BR112013014392B1 (enExample)
CA (2) CA2820451C (enExample)
DK (1) DK2673285T3 (enExample)
ES (1) ES2642287T3 (enExample)
HU (1) HUE036658T2 (enExample)
MX (1) MX348084B (enExample)
NZ (1) NZ623574A (enExample)
PL (1) PL2673285T3 (enExample)
PT (1) PT2673285T (enExample)
RU (1) RU2601550C2 (enExample)
WO (1) WO2012076989A1 (enExample)
ZA (1) ZA201304150B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587490A (en) * 2010-08-20 2013-03-28 Greentide Ltd Anti-Microbial Compounds containing compounds with a sugar substituent
CN103619863B (zh) * 2011-03-22 2016-03-16 沃克哈特有限公司 酮内酯化合物的制备方法
US9346828B2 (en) 2013-06-07 2016-05-24 Wisconsin Alumni Research Foundation Forazolines, compositions thereof and uses thereof
DK3328843T3 (da) 2015-07-27 2023-01-09 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
AU2016299486B2 (en) 2015-07-27 2019-08-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
DK3330259T3 (da) 2015-07-27 2020-08-10 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
EP3331864B1 (en) 2015-08-04 2021-11-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX384527B (es) 2015-10-12 2025-03-14 Chong Kun Dang Pharmaceutical Corp Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
CN108778290A (zh) * 2016-01-12 2018-11-09 沃克哈特有限公司 用于治疗细菌感染的药物组合物
EP3402467A1 (en) * 2016-01-12 2018-11-21 Wockhardt Limited Pharmaceutical compositions
US10485812B2 (en) * 2016-01-12 2019-11-26 Wockhardt Limited Stable antibacterial composition
WO2018167675A1 (en) * 2017-03-16 2018-09-20 Wockhardt Limited A process for preparing ketolide compounds
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
TWI748491B (zh) 2019-05-31 2021-12-01 韓商鐘根堂股份有限公司 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑高鄰苯二甲醯亞胺衍生化合物及包含彼之醫藥組合物
CA3159633A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. Mrgprx2 antagonists and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
ATE296308T1 (de) 1996-09-04 2005-06-15 Abbott Lab 6-o-substituierte ketoliden mit antibakteriellen wirkung
WO1999021870A1 (en) * 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Erythromycin a 11, 12-carbamate derivatives
HRP980189B1 (en) * 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
FR2777282B1 (fr) * 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
ES2313975T3 (es) 2000-08-22 2009-03-16 Basilea Pharmaceutica Ag Nuevos macrolidos con actividad antibacteriana.
DE60124594T2 (de) 2000-12-21 2007-10-04 Glaxo Group Ltd., Greenford Makrolidantibiotika
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
GB0127349D0 (en) 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
US6995143B2 (en) * 2002-02-28 2006-02-07 Basilea Pharmaceutica Ag Macrolides with antibacterial activity
US6727229B2 (en) 2002-08-19 2004-04-27 Enanta Pharmaceuticals, Inc. 11,12-substituted lactone ketolide derivatives having antibacterial activity
WO2004108744A2 (en) * 2003-05-19 2004-12-16 Prasad K Deshpande Azalides and azaketolides having antimicrobial activity
BRPI0513903A (pt) * 2004-07-28 2008-05-20 Ranbaxy Lab Ltd derivados de cetolìdeos úteis como agentes antimicrobianos, seus processos de preparação e composições farmacêuticas compreendendo os mesmos
EP2056844A4 (en) 2006-08-24 2010-11-24 Wockhardt Research Center NEW MACROLIDS AND KETOLIDS WITH ANTIMICROBIAL EFFECT
JP5642548B2 (ja) * 2007-09-17 2014-12-17 エナンタ ファーマシューティカルズ インコーポレイテッド 6,11−架橋ビアリールマクロライド
US8552162B2 (en) 2008-05-09 2013-10-08 Enanta Pharmaceuticals, Inc. Processes for the preparation of 2 fluoro 6-11 bicyclic erythromycin derivatives
BRPI1011959A2 (pt) 2009-05-27 2016-04-26 Wockhardt Research Center compostos de cetolídeo tendo atividade antimicrobiana.

Also Published As

Publication number Publication date
BR112013014392A2 (pt) 2016-07-19
JP2015172085A (ja) 2015-10-01
ES2642287T3 (es) 2017-11-16
CN103384676A (zh) 2013-11-06
PT2673285T (pt) 2017-10-19
JP5851516B2 (ja) 2016-02-03
US20160083412A1 (en) 2016-03-24
WO2012076989A1 (en) 2012-06-14
CN105669803A (zh) 2016-06-15
HUE036658T2 (hu) 2018-07-30
KR101657751B1 (ko) 2016-09-19
US20140005133A1 (en) 2014-01-02
EP3216798A3 (en) 2017-10-25
JP6102991B2 (ja) 2017-03-29
MX2013006461A (es) 2013-10-01
CA2820451A1 (en) 2012-06-14
EP2673285B1 (en) 2017-07-19
PL2673285T3 (pl) 2017-12-29
EP3216798A2 (en) 2017-09-13
RU2013131234A (ru) 2015-01-20
ZA201304150B (en) 2014-11-26
US9175031B2 (en) 2015-11-03
MX348084B (es) 2017-05-26
KR20130112911A (ko) 2013-10-14
RU2601550C2 (ru) 2016-11-10
NZ623574A (en) 2015-07-31
JP2013544877A (ja) 2013-12-19
AU2011340204A1 (en) 2013-07-04
CA2820451C (en) 2017-12-12
CA2964104A1 (en) 2012-06-14
EP2673285A1 (en) 2013-12-18
CN103384676B (zh) 2016-02-03
AU2011340204B2 (en) 2016-04-14
DK2673285T3 (en) 2017-10-16

Similar Documents

Publication Publication Date Title
BR112013014392B1 (pt) Compostos cetolídeos, seu uso e processo de preparação, bem como composição farmacêutica compreendendo os mesmos
CA2244519C (en) C-4":substituted macrolide antibiotics
CN102459296B (zh) 具有抗微生物活性的酮内酯类化合物
EP2681222B1 (en) Process for preparation of ketolide intermediates
HRP980316A2 (en) 9-oxime erythromycin derivatives
WO2000034297A1 (en) Carbamate and carbazate ketolide antibiotics
CZ20011512A3 (cs) Nová makrolidová antibiotika
UA70972C2 (uk) 13-членні азаліди і їх застосування як антибіотиків
JP2004517819A (ja) ケトライド抗菌剤
WO2009139181A1 (ja) 4員環構造を有する10a-アザライド化合物
NZ611653A (en) Ketolide compounds
NZ611653B (en) Ketolide compounds
JP2014058508A (ja) 9位オキシム置換マクロライド誘導体

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.